Our innovation
Targeted small molecule therapeutic
drug for IL-1β-related diseases
The first-in-class oral inhibitor of IL-1β production may be a game-changer in the treatment of various IL-1β-related diseases that currently lack effective treatment options such as autoinflammatory diseases as well as immune-mediated and non-immune mediated inflammatory diseases.
IL-1β serves as a crucial mediator in immune and inflammatory responses. This cytokine plays a pivotal role in defending the body against pathogens such as viruses and bacteria, while also contributing to the regulation of tissue repair processes.
However, despite the important role of IL-1β in the immune response, its prolonged expression over time is associated with a wide variety of diseases.
Alosertib
